Stoyanova Lab News

Identification of a new driver and therapeutic target for a highly aggressive subtype of prostate cancer

Exciting new results from our lab identifying a new driver and therapeutic target for highly aggressive metastatic prostate cancer with neuroendocrine features are published in PNAS. Congratulations En-Chi!

News Stanford
Jordan Lee, undergraduate student at Stanford, joins the lab. Welcome Jordan!

Jordan Lee, undergraduate student at Stanford, joins the lab. Welcome Jordan!

News Stanford
Exciting news: Mark Buckup and team awarded DEBUT Honorable Mention by the National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Exciting news: Mark Buckup and team awarded DEBUT Honorable Mention by the National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Mark and his team receives Honorable Mention designation at the Design by Biomedical Undergraduate Teams (DEBUT) Competition hosted by the NIBIB and VentureWell. Congratulations!

News Stanford

Stoyanova lab launches it’s first manuscript

Excellent work by Stoyanova Lab, showing that loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to anti-androgen therapies.

News Stanford

Dr. Ali Ghoochani, Postdoctoral Fellow in Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Early Investigator Award for his project

Dr. Ali Ghoochani, Postdoctoral Fellow in Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Early Investigator Award for his project title:

“Ferroptosis Induction is a Novel Therapeutic Strategy for Advanced Prostate Cancer”

The overall goal of the proposed research is to develop novel therapeutic strategies that improve outcomes for men with lethal prostate cancer. In the proposed research, we aim to assess the therapeutic potential of ferroptosis induction (Iron-dependent cell death) by erastin treatment in advanced prostate cancer.  We will also evaluate the therapeutic potential of ferroptosis induction in combination with FDA approved second-generation anti-androgens Enzalutamide and Abiraterone. Additionally, we will investigate the molecular mechanisms through which ferroptosis induction affects prostate cancer. Completion of the proposed research will lead to the development of novel therapeutic strategies for advanced prostate cancer and thus significantly reduce mortalities associated with lethal prostate cancer.

News Stanford
Welcome Dr. Shiqin Liu

Welcome Dr. Shiqin Liu

The Stoyanova lab is excited to announce the addition of Postdoctoral Fellow, Dr. Shiqin Liu,  to the team.

Welcome!

News Stanford
Stoyanova Lab awarded NCI Small Grants Program for Cancer Research award for the project titled:

Stoyanova Lab awarded NCI Small Grants Program for Cancer Research award for the project titled:

Stoyanova Lab awarded NCI Small Grants Program for Cancer Research award for the project titled:

“Elucidating novel mechanisms underlying prostate cancer development”

The major goals of the proposed project are to define novel mechanisms through which Trop2 contributes to the development of advanced prostate cancer. The study will also develop new the therapeutic strategies to target Trop2 activity. Completion of the proposed research will give us insights into new mechanisms underlying the development of aggressive prostate cancer and open novel avenues for therapeutic intervention.

Congratulations!

News Stanford
2018 Canary Challenge Fundraiser

2018 Canary Challenge Fundraiser

Thank you to everyone who came out to support the important cause of cancer early detection.  Together, the Canary Center Team raised over $30,000 this year at the  2018 Canary Challenge.   We are overjoyed at this achievement and are grateful for everyone’s committment.

Thank you and Congratulations to all participants and volunteers!

Please visit www.canarychallenge.com to obtain more information.

News Stanford
Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Idea Development Award for project title:

Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Idea Development Award for project title:

Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Idea Development Award for project title:

“Trop2 as a novel driver and therapeutic target for castration-resistant prostate cancer”

The proposed research aims to define new drives and therapeutic targets for advanced prostate cancer. We have recently demonstrated that cell surface protein, Trop2, represents a new promising therapeutic target for advanced prostate cancer.  The proposed project will evaluate novel strategies to target Trop2 in aggressive prostate cancer. Identifying new therapeutic strategies and pathways and mechanisms that contribute to the development of aggressive prostate cancer will significantly advance the field of prostate cancer research.

Congratulations!

News Stanford
Dr. Meghan Rice, PhD, Postdoctoral Fellow in Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Early Investigator Research Award for her project title:

Dr. Meghan Rice, PhD, Postdoctoral Fellow in Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Early Investigator Research Award for her project title:

Dr. Meghan Rice, PhD, Postdoctoral Fellow in Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Early Investigator Research Award for her project title:

“Defining the Role and Therapeutic Potential of Notch Signaling in Aggressive Prostate Cancer”

The overall goal of this proposal is to understand the mechanisms causing aggressive prostate cancer. The proposed project will investigate the role of Notch signaling pathway in prostate cancer to understand the mechanism through which Notch can drive the aggressive disease and determine the requirement of Notch for tumor maintenance. Additionally, we will test new treatment strategies involving two types of Notch inhibitors alone, and in combination with current standard of care treatments for castration resistant disease. This study will facilitate our understanding of fundamental molecular mechanisms underlying the development of aggressive prostate cancer and direct novel strategies regarding new combination therapies for the advanced disease.

Congratulations Dr. Rice!

News Stanford